All In Biotech

Investigational drug · Phase 2

GKL-006

Also called: iNKT cells

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas, Hepatocellular Carcinoma (HCC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "GKL-006"

First trial start

2025

Aug 14, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "GKL-006", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Pancreatic Cancer
  • Ductal Adenocarcinoma of Pancreas
  • Hepatocellular Carcinoma (HCC)
  • Unresectable Hepatocellular Cancer

Approved drugs for the same conditions: Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "GKL-006" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2,029 on PubMed

Also in development for Advanced Pancreatic Cancer

  • LM-108Phase 36 trials

    LaNova Medicines Limited · Advanced Solid Tumor, Advanced Pancreatic Cancer, Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

  • MRG004APhase 31 trial

    Lepu Biopharma Co., Ltd. · Advanced Pancreatic Cancer

  • BotensilimabAGEN1181, 8541APhase 24 trials

    Agenus Inc. · Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated

  • NLM-001Phase 22 trials

    Nelum Corp · Untreated, Advanced Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

  • BalstililmabPhase 21 trial

    Nelum Corp · Untreated, Advanced Pancreatic Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.